The Lynx Group

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Videos — January 10, 2018

Featuring:

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: